Cytori to Include Raynaud’s Phenomenon in Its Scleroderma Cell Therapy Program
News
Cytori Therapeutics will expand the development of its ECCS-50 scleroderma treatment to include secondary Raynaud’s phenomenon (RP), under the brand Habeo Cell Therapy. Habeo means “to hold” in Latin and represents ... Read more